Amylase - urine
Definition
This is a test that measures the amount of amylase in the urine. Amylase is an enzyme that helps digest carbohydrates. It is produced mainly in the pancreas and the glands that make saliva.
Amylase may also be measured with a blood test.
How the Test is Performed
A urine sample is needed. The test may be performed using a:
How to Prepare for the Test
Many medicines can interfere with the test results.
- Your health care provider will tell you if you need to stop taking any medicines before you have this test.
- Do not stop or change your medicines without talking to your provider first.
How the Test will Feel
The test involves only normal urination. There is no discomfort.
Why the Test is Performed
This test is sometimes done to help diagnose pancreatitis and other diseases that affect the pancreas.
Normal Results
The normal range is:
- Females: 21 to 447 U/L (0.36 to 7.60 µKat/L)
- Males: 16 to 491 U/L (0.27 to 8.35 µKat/L)
The example above shows the common measurement range for results for these tests. Normal value ranges may vary slightly among different laboratories. Talk to your provider about the meaning of your specific test results.
What Abnormal Results Mean
An increased amount of amylase in the urine is called amylasuria. Increased urine amylase levels may be a sign of:
- Acute pancreatitis
- Alcohol consumption
- Cancer of the pancreas, ovaries, or lungs
- Cholecystitis
- Ectopic or ruptured tubal pregnancy
- Gallbladder disease
- Infection of the salivary glands (called sialadenitis, may be caused by bacteria, mumps or a blockage)
- Intestinal obstruction
- Pancreatic duct obstruction
- Pelvic inflammatory disease
- Perforated ulcer
Decreased amylase levels may be due to:
- Damage to the pancreas
- Kidney disease
- Macroamylasemia
References
Siddiqi HA, Rabinowitz S, Axiotis CA. Laboratory diagnosis of gastrointestinal and pancreatic disorders. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 23.
Vege SS. Acute pancreatitis. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 11th ed. Philadelphia, PA: Elsevier; 2021:chap 58.
Review Date: 7/1/2025
Reviewed By: Frank D. Brodkey, MD, FCCM, Associate Professor, Section of Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language.
© 1997-
A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
All content on this site including text, images, graphics, audio, video, data, metadata, and compilations is protected by copyright and other intellectual property laws. You may view the content for personal, noncommercial use. Any other use requires prior written consent from Ebix. You may not copy, reproduce, distribute, transmit, display, publish, reverse-engineer, adapt, modify, store beyond ordinary browser caching, index, mine, scrape, or create derivative works from this content. You may not use automated tools to access or extract content, including to create embeddings, vectors, datasets, or indexes for retrieval systems. Use of any content for training, fine-tuning, calibrating, testing, evaluating, or improving AI systems of any kind is prohibited without express written consent. This includes large language models, machine learning models, neural networks, generative systems, retrieval-augmented systems, and any software that ingests content to produce outputs. Any unauthorized use of the content including AI-related use is a violation of our rights and may result in legal action, damages, and statutory penalties to the fullest extent permitted by law. Ebix reserves the right to enforce its rights through legal, technological, and contractual measures.
All rights reserved